275 related articles for article (PubMed ID: 33328961)
1. P2X4R Overexpression Upregulates Interleukin-6 and Exacerbates 6-OHDA-Induced Dopaminergic Degeneration in a Rat Model of PD.
Ma J; Gao J; Niu M; Zhang X; Wang J; Xie A
Front Aging Neurosci; 2020; 12():580068. PubMed ID: 33328961
[TBL] [Abstract][Full Text] [Related]
2. Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Vecchia DD; Kanazawa LKS; Wendler E; Hocayen PAS; Vital MABF; Takahashi RN; Da Cunha C; Miyoshi E; Andreatini R
Brain Res Bull; 2021 Mar; 168():63-73. PubMed ID: 33359641
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial unfolded protein response: An emerging pathway in human diseases.
Zhu L; Zhou Q; He L; Chen L
Free Radic Biol Med; 2021 Feb; 163():125-134. PubMed ID: 33347985
[TBL] [Abstract][Full Text] [Related]
4. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease.
Cuevas E; Burks S; Raymick J; Robinson B; Gómez-Crisóstomo NP; Escudero-Lourdes C; Lopez AGG; Chigurupati S; Hanig J; Ferguson SA; Sarkar S
Nutr Neurosci; 2022 Jul; 25(7):1374-1391. PubMed ID: 33345721
[TBL] [Abstract][Full Text] [Related]
5. A Specific Diplotype H1j/H2 of the MAPT Gene Could Be Responsible for Parkinson's Disease with Dementia.
Smaili I; Hajjaj I; Razine R; Tibar H; Salmi A; Bouslam N; Moussa A; Regragui W; Bouhouche A
Case Rep Genet; 2020; 2020():8813344. PubMed ID: 33343949
[TBL] [Abstract][Full Text] [Related]
6. Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model: This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get". The articles are accompanied by a Preface "How good are cellular models?".
Lashuel HA
J Neurochem; 2021 May; 157(4):891-898. PubMed ID: 33336386
[TBL] [Abstract][Full Text] [Related]
7. Transient Receptor Potential Channels as an Emerging Target for the Treatment of Parkinson's Disease: An Insight Into Role of Pharmacological Interventions.
Vaidya B; Sharma SS
Front Cell Dev Biol; 2020; 8():584513. PubMed ID: 33330461
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson's Disease in the Elderly.
Janiri D; Petracca M; Moccia L; Tricoli L; Piano C; Bove F; Imbimbo I; Simonetti A; Di Nicola M; Sani G; Calabresi P; Bentivoglio AR
Front Psychiatry; 2020; 11():581144. PubMed ID: 33329124
[No Abstract] [Full Text] [Related]
9. The Effect of Endurance Training on Brain-Derived Neurotrophic Factor and Inflammatory Markers in Healthy People and Parkinson's Disease. A Narrative Review.
Małczyńska-Sims P; Chalimoniuk M; Sułek A
Front Physiol; 2020; 11():578981. PubMed ID: 33329027
[No Abstract] [Full Text] [Related]
10. LncRNA-T199678 Mitigates α-Synuclein-Induced Dopaminergic Neuron Injury via miR-101-3p.
Bu LL; Xie YY; Lin DY; Chen Y; Jing XN; Liang YR; Peng SD; Huang KX; Tao EX
Front Aging Neurosci; 2020; 12():599246. PubMed ID: 33328976
[TBL] [Abstract][Full Text] [Related]
11. Novel compound heterozygous of PARKIN causes early-onset Parkinson's disease.
Yu LH; Peng GP; Yuan Y; Liu XY; Ji F; Li Y; He FP; Luo BY; Ke Q
Neurosci Lett; 2021 Jan; 744():135597. PubMed ID: 33373675
[TBL] [Abstract][Full Text] [Related]
12. Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease.
Martínez-Fernández R; Máñez-Miró JU; Rodríguez-Rojas R; Del Álamo M; Shah BB; Hernández-Fernández F; Pineda-Pardo JA; Monje MHG; Fernández-Rodríguez B; Sperling SA; Mata-Marín D; Guida P; Alonso-Frech F; Obeso I; Gasca-Salas C; Vela-Desojo L; Elias WJ; Obeso JA
N Engl J Med; 2020 Dec; 383(26):2501-2513. PubMed ID: 33369354
[TBL] [Abstract][Full Text] [Related]
13. Freezing of Gait in Parkinson's Disease: Invasive and Noninvasive Neuromodulation.
Rahimpour S; Gaztanaga W; Yadav AP; Chang SJ; Krucoff MO; Cajigas I; Turner DA; Wang DD
Neuromodulation; 2021 Jul; 24(5):829-842. PubMed ID: 33368872
[TBL] [Abstract][Full Text] [Related]
14. Imaging Transcriptomics in Neurodegenerative Diseases.
Mroczek M; Desouky A; Sirry W
J Neuroimaging; 2021 Mar; 31(2):244-250. PubMed ID: 33368775
[TBL] [Abstract][Full Text] [Related]
15. MOBP and HIP1 in multiple system atrophy: New α-synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis.
Bettencourt C; Miki Y; Piras IS; de Silva R; Foti SC; Talboom JS; Revesz T; Lashley T; Balazs R; Viré E; Warner TT; Huentelman MJ; Holton JL
Neuropathol Appl Neurobiol; 2021 Aug; 47(5):640-652. PubMed ID: 33368549
[TBL] [Abstract][Full Text] [Related]
16. The Future of GDNF in Parkinson's Disease.
Manfredsson FP; Polinski NK; Subramanian T; Boulis N; Wakeman DR; Mandel RJ
Front Aging Neurosci; 2020; 12():593572. PubMed ID: 33364933
[No Abstract] [Full Text] [Related]
17. Cognitive decline in Parkinson's disease is associated with reduced complexity of EEG at baseline.
Keller SM; Gschwandtner U; Meyer A; Chaturvedi M; Roth V; Fuhr P
Brain Commun; 2020; 2(2):fcaa207. PubMed ID: 33364601
[TBL] [Abstract][Full Text] [Related]
18. Similarities Between Depression and Neurodegenerative Diseases: Pathophysiology, Challenges in Diagnosis and Treatment Options.
Hussain M; Kumar P; Khan S; Gordon DK; Khan S
Cureus; 2020 Nov; 12(11):e11613. PubMed ID: 33364130
[TBL] [Abstract][Full Text] [Related]
19. Changes in Prefrontal Cortical Activity During Walking and Cognitive Functions Among Patients With Parkinson's Disease.
Ranchet M; Hoang I; Cheminon M; Derollepot R; Devos H; Perrey S; Luauté J; Danaila T; Paire-Ficout L
Front Neurol; 2020; 11():601686. PubMed ID: 33362703
[No Abstract] [Full Text] [Related]
20. Effect of Bone Marrow Stromal Cells in Parkinson's Disease Rodent Model: A Meta-Analysis.
Liu J; He J; Huang Y; Hu Z
Front Aging Neurosci; 2020; 12():539933. PubMed ID: 33362527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
